---
id: sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026
kind: topic
title: "HSA 上市后监测指南 2026 年"
url: https://ik.sg/zh/knowledge/topic/sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026
language: zh-Hans
evidence_status: recorded
collection_as_of: 2026-11-22
---

# HSA 上市后监测指南 2026 年

卫生科学局的 2026 年上市后警戒指南阐明治疗产品的安全报告职责和提交要求。

## 记录详情

- **别称:** HSA post-marketing vigilance; therapeutic product adverse-event reporting Singapore; CTGTP vigilance guidance
- **证据类型:** mixed
- **说明:** HSA’s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.
- **所属:** [医疗保健](https://ik.sg/zh/knowledge/topic/sgtopic.healthcare)
- **Primary domain:** healthcare

## 探索关联

- 文章: [HSA 上市后警戒指南 2026](https://ik.sg/zh/knowledge/article/sgkb.healthcare.hsa-post-marketing-vigilance-guidance-2026)
- 主题: [医疗保健](https://ik.sg/zh/knowledge/topic/sgtopic.healthcare)
- 人物与机构: [HSA 上市后监测指南第 6 版](https://ik.sg/zh/knowledge/entity/sg.guidance.hsa-post-marketing-vigilance-v6)
- 历期数据: [HSA上市后警戒指南第 6 版](https://ik.sg/zh/knowledge/observation/sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision)

日期表示本记录的统计期间与适用范围。核验日期并不代表规则目前已经生效。 知识库持续扩充中。发布数量表示现有内容，并不代表已覆盖新加坡的全部知识。
